| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 128, 471-483, Copyright © 1987 by American Society for Investigative Pathology
REGULAR ARTICLES |
C Lundberg, F Marceau and TE Hugli
Hemodynamic and hematologic changes occurring after intravascular complement activation have implicated the anaphylatoxins in this response. In this study, the hemodynamic and hematologic effects of purified C5a were investigated in rabbits; and involvement of prostanoids, histamine, and polymorphonuclear leukocytes (PMNs) were examined. The anaphylatoxin C5a induces a reversible systemic arterial hypotension which coincides with an increase in central venous pressure (CVP), decreased cardiac output (CO), increased plasma prostanoid levels, as well as neutropenia. Total peripheral resistance (TPR) remained unchanged. The cyclooxygenase inhibitor indomethacin abolished the C5a-induced hypotension and normalized plasma prostanoid levels without altering the C5a-induced neutropenia. The thromboxane (Tx) A2 synthetase inhibitor dazoxiben reduced TxB2 plasma levels and increased 6-keto-prostaglandin PGF1 alpha and PGE2 levels without altering the hypotensive response. However, with dazoxiben treatment both TPR and CVP decreased. The H2-receptor antagonist cimetidine reduced C5a- induced hypotension and diminished prostanoid release. Both the hypotensive response and elevated prostanoid release were observed after C5a challenge in animals rendered neutropenic prior to challenge. It is concluded that C5a-induced arterial hypotension in the rabbit is a PMN-independent reaction, mediated through cyclooxygenase products and, to some degree, by histamine. The mechanism producing systemic arterial hypotension does not seem to involve peripheral vasodilation but appears to be a secondary effect of pulmonary vasoconstriction, possibly mediated by TxA2.
This article has been cited by other articles:
 |
|
 |
|
  T. Kurizaki, M. Abe, S. D. Sanderson, C. A. Enke, and J. Baranowska-Kortylewicz Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides Mol. Cancer Ther., January 1, 2004; 3(1): 85 - 91. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Li, V. M. Holers, S. A. Boackle, and C. M. Blatteis Modulation of Mouse Endotoxic Fever by Complement Infect. Immun., May 1, 2002; 70(5): 2519 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Laudes, J. C. Chu, S. Sikranth, M. Huber-Lang, R.-F. Guo, N. Riedemann, J. V. Sarma, A. H. Schmaier, and P. A. Ward Anti-C5a Ameliorates Coagulation/Fibrinolytic Protein Changes in a Rat Model of Sepsis Am. J. Pathol., May 1, 2002; 160(5): 1867 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Jansen, B. Eisele, I. W. de Jong, A. Chang, U. Delvos, F. B. Taylor Jr., and C. E. Hack Effect of C1 Inhibitor on Inflammatory and Physiologic Response Patterns in Primates Suffering from Lethal Septic Shock J. Immunol., January 1, 1998; 160(1): 475 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Audet, F. Rioux, G. Drapeau, and F. Marceau Cardiovascular Effects of Sar-[D-Phe8]des-Arg9-Bradykinin, a Metabolically Protected Agonist of B1 Receptor for Kinins, in the Anesthetized Rabbit Pretreated with a Sublethal Dose of Bacterial Lipopolysaccharide J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 6 - 15. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Miyamoto, H. Matsuda, and Y. Kawashima Deleterious Effects of Complement Activation on the Lungs during Extracorporeal Circulation and Its Inhibition by FUT-175 J Biomater Appl, July 1, 1989; 4(1): 56 - 68. [Abstract]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
